Geron Corporation (GERN)Healthcare | Biotechnology | Foster City, United States | NasdaqGS
1.68 USD
-0.01
(-0.592%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.69 +0.01 (0.577%) ⇧ (April 17, 2026, 7:07 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:09 p.m. EDT
Geron is a polarizing biotech play currently caught between near-term cost-cutting exhaustion and long-term pipeline potential. While fundamentals remain weak with negative earnings flow and a restructuring drive until 2026, the long-dated options chain signals that smart money is pricing in a substantial dividend or stock appreciation play by 2027. However, the lack of tangible recent catalysts and ongoing losses make it a speculative 'hold' for now, suitable only for high-risk capital. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.092527 |
| MSTL | 0.155845 |
| AutoARIMA | 0.158296 |
| AutoETS | 0.158744 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 79% |
| H-stat | 0.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.089 |
| Excess Kurtosis | 0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 54.009 |
| Revenue per Share | 0.276 |
| Market Cap | 1,076,712,576 |
| Forward P/E | 21.00 |
| Beta | 0.67 |
| Profit Margins | -45.41% |
| Website | https://www.geron.com |
As of April 18, 2026, 10:09 p.m. EDT: The options data reveals a significant divergence in sentiment. For the near term (April '26), put volume aggressively dominates, with massive open interest at the $1.0 strike compared to negligible activity at strikes above current price. However, looking at longer-dated expirations (June, Sept, Jan '27), the flow shifts decisively bullish. Speculators are heavily accumulating call open interest in the $2.00 - $3.00 range for the Jan '27 strike. This suggests a sentiment narrative of 'hedging downside risk now while anticipating a significant rally in 2027,' likely driven by the company's 2026 profitability targets and pipeline potential.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.24444449 |
| Address1 | 919 East Hillsdale Boulevard |
| Address2 | Suite 250 |
| All Time High | 71.7155 |
| All Time Low | 0.75 |
| Ask | 1.69 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Analyst Rating | 2.2 - Buy |
| Average Daily Volume10 Day | 20,540,560 |
| Average Daily Volume3 Month | 18,475,090 |
| Average Volume | 18,475,090 |
| Average Volume10Days | 20,540,560 |
| Beta | 0.671 |
| Bid | 1.43 |
| Bid Size | 1 |
| Board Risk | 4 |
| Book Value | 0.353 |
| City | Foster City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.68 |
| Current Ratio | 4.664 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.74 |
| Day Low | 1.66 |
| Debt To Equity | 54.009 |
| Display Name | Geron |
| Earnings Call Timestamp End | 1,772,024,400 |
| Earnings Call Timestamp Start | 1,772,024,400 |
| Earnings Timestamp | 1,772,026,200 |
| Earnings Timestamp End | 1,778,070,600 |
| Earnings Timestamp Start | 1,778,070,600 |
| Ebitda | -51,079,000 |
| Ebitda Margins | -0.27778 |
| Enterprise To Ebitda | -16.449 |
| Enterprise To Revenue | 4.569 |
| Enterprise Value | 840,188,032 |
| Eps Current Year | -0.02 |
| Eps Forward | 0.08 |
| Eps Trailing Twelve Months | -0.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.6344 |
| Fifty Day Average Change | 0.045599937 |
| Fifty Day Average Change Percent | 0.027900109 |
| Fifty Two Week Change Percent | 24.444448 |
| Fifty Two Week High | 2.01 |
| Fifty Two Week High Change | -0.33000004 |
| Fifty Two Week High Change Percent | -0.16417913 |
| Fifty Two Week Low | 1.04 |
| Fifty Two Week Low Change | 0.64 |
| Fifty Two Week Low Change Percent | 0.61538464 |
| Fifty Two Week Range | 1.04 - 2.01 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 838,819,800,000 |
| Float Shares | 510,783,124 |
| Forward Eps | 0.08 |
| Forward P E | 21.0 |
| Free Cashflow | -78,356,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 258 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.9742 |
| Gross Profits | 179,136,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00081 |
| Held Percent Institutions | 0.77924 |
| Implied Shares Outstanding | 640,900,330 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,405,987,200 |
| Last Split Factor | 1,058:1000 |
| Long Business Summary | Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California. |
| Long Name | Geron Corporation |
| Market | us_market |
| Market Cap | 1,076,712,576 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_215864 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -83,500,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,076,712,554 |
| Number Of Analyst Opinions | 5 |
| Open | 1.74 |
| Operating Cashflow | -111,037,000 |
| Operating Margins | -0.17719 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 650 473 7700 |
| Post Market Change | 0.00970006 |
| Post Market Change Percent | 0.57738453 |
| Post Market Price | 1.6897 |
| Post Market Time | 1,776,467,239 |
| Previous Close | 1.69 |
| Price Eps Current Year | -84.0 |
| Price Hint | 4 |
| Price To Book | 4.759207 |
| Price To Sales Trailing12 Months | 5.855486 |
| Profit Margins | -0.4541 |
| Quick Ratio | 3.56 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.16667 |
| Region | US |
| Regular Market Change | -0.0100001 |
| Regular Market Change Percent | -0.591722 |
| Regular Market Day High | 1.74 |
| Regular Market Day Low | 1.66 |
| Regular Market Day Range | 1.66 - 1.74 |
| Regular Market Open | 1.74 |
| Regular Market Previous Close | 1.69 |
| Regular Market Price | 1.68 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 21,774,648 |
| Return On Assets | -0.05535 |
| Return On Equity | -0.32991 |
| Revenue Growth | 0.01 |
| Revenue Per Share | 0.276 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 9 |
| Shares Outstanding | 640,900,330 |
| Shares Percent Shares Out | 0.1196 |
| Shares Short | 76,666,335 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 60,621,875 |
| Short Name | Geron Corporation |
| Short Percent Of Float | 0.1197 |
| Short Ratio | 4.3 |
| Source Interval | 15 |
| State | CA |
| Symbol | GERN |
| Target High Price | 5.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 3.4 |
| Target Median Price | 4.0 |
| Total Cash | 357,919,008 |
| Total Cash Per Share | 0.559 |
| Total Debt | 121,992,000 |
| Total Revenue | 183,880,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.38685 |
| Two Hundred Day Average Change | 0.29314995 |
| Two Hundred Day Average Change Percent | 0.21137826 |
| Type Disp | Equity |
| Volume | 21,774,648 |
| Website | https://www.geron.com |
| Zip | 94,404 |